Betaxolol
As of the edition of 20 October 2026, Betaxolol is a small molecule: marketed, first approved in 1982 (FR); acts on ADRB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Small molecule
- Brand name
- Betoptic
- First approved
- 10 May 1982 (FR)
- Approvals on record
- 9 in 3 regions
- Holder of the most recent approval
- Alcon; 6 holders in all
- Registered trials
- 3, 0 stopped early
- Disease areas
- Eye
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Betaxolol.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | P08588 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 1 | 0 | 0 |
| All trials | 3 |